S
17.83
-0.04 (-0.22%)
| Penutupan Terdahulu | 17.87 |
| Buka | 18.08 |
| Jumlah Dagangan | 1,422,463 |
| Purata Dagangan (3B) | 3,154,080 |
| Modal Pasaran | 13,148,697,600 |
| Harga / Buku (P/B) | 28.58 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 18 Feb 2025 - 24 Feb 2025 |
| EPS Cair (TTM) | -0.230 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.42% |
| Nisbah Semasa (MRQ) | 8.31 |
| Aliran Tunai Operasi (OCF TTM) | -112.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -62.82 M |
| Pulangan Atas Aset (ROA TTM) | -31.47% |
| Pulangan Atas Ekuiti (ROE TTM) | -73.21% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Summit Therapeutics Inc. | Menurun | Menaik |
AISkor Stockmoo
1.3
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.25 |
|
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 84.36% |
| % Dimiliki oleh Institusi | 11.75% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Darwin Global Management, Ltd. | 30 Sep 2024 | 1,084,880 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 44.00 (HC Wainwright & Co., 146.78%) | Beli |
| Median | 31.50 (76.67%) | |
| Rendah | 23.00 (Citigroup, 29.00%) | Pegang |
| Purata | 33.33 (86.93%) | |
| Jumlah | 5 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 19.96 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 11 Dec 2024 | 30.00 (68.26%) | Beli | 18.77 |
| Jefferies | 06 Dec 2024 | 31.00 (73.86%) | Beli | 18.54 |
| HC Wainwright & Co. | 18 Nov 2024 | 44.00 (146.78%) | Beli | 18.98 |
| 31 Oct 2024 | 44.00 (146.78%) | Beli | 18.59 | |
| JMP Securities | 04 Nov 2024 | 32.00 (79.47%) | Beli | 19.96 |
| Citigroup | 27 Sep 2024 | 23.00 (29.00%) | Pegang | 20.89 |
| Stifel | 25 Sep 2024 | 40.00 (124.34%) | Beli | 22.64 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Dec 2024 | Pengumuman | Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 26 Nov 2024 | Pengumuman | Summit Therapeutics to Present at Upcoming Investor Conferences |
| 21 Nov 2024 | Pengumuman | Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 30 Oct 2024 | Pengumuman | Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 |
| 28 Oct 2024 | Pengumuman | From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update |
| 23 Oct 2024 | Pengumuman | Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024 |
| 04 Oct 2024 | Pengumuman | Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 03 Oct 2024 | Pengumuman | Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |